The reiteration of a Buy rating and maintenance of a $171 price target by a reputable analyst firm like Canaccord Genuity could positively influence investor sentiment towards BioNTech. This endorsement reflects confidence in the company's future performance, potentially leading to an uptick in stock price in the short term.